Retrospective Study Comparing Treatment Outcomes in Obstetric Patients With Iron Deficiency Anemia Treated With and Without Intravenous Ferric Carboxymaltose.

Autor:	Li M; Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore, SGP., Wright A; Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore, SGP., Rahim AM; Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore, SGP., Tan KH; Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore, SGP., Tagore S; Maternal Fetal Medicine, KK Women's and Children's Hospital, Singapore, SGP.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Mar 07; Vol. 16 (3), pp. e55713. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).
DOI:	10.7759/cureus.55713
Abstrakt:	Introduction Iron deficiency anemia is associated with an increased risk of adverse maternal and perinatal outcomes. Intravenous iron preparation containing ferric carboxymaltose has been shown to be a safe and effective way of increasing hemoglobin (Hb) and mean corpuscular volume (MCV) levels and reducing the need for blood transfusion. In our center, it used to be given as an inpatient procedure because of the risks of potential drug reactions. In 2021, we initiated the administration of intravenous ferric carboxymaltose as an outpatient procedure. We compared the outcomes of patients between 2021 and 2023 after the initiation of outpatient administration of intravenous ferric carboxymaltose in 127 obstetric patients with iron deficiency anemia in the second and third trimesters. Methods In this study conducted in a large maternity unit in Singapore between 2021 to 2023, we compared the changes in maternal hematological parameters among obstetric patients with iron deficiency anemia presenting to the day care unit in the second or third trimester with a Hb level of <8 g/dl treated with a single dose of ferric carboxymaltose injection (Ferinject) against a control group who were referred for treatment but defaulted on and declined treatment. Results Ferric carboxymaltose significantly increased the Hb and MCV levels at delivery in obstetric patients with iron deficiency. The mean Hb at delivery was 10.8 g/dL in the case group compared to 8.8 g/dL in the control group. The percentage of patients with Hb ≥10.0 g/dL was 73.4% in the case group compared to 27.8% in the control group. The incidence of adverse side effects was low and mild (2/127; 1.6%). None of the patients received were hospitalized because of ferric carboxymaltose. Conclusion A single injection dose of ferric carboxymaltose as an outpatient antenatal procedure was easily administered and well tolerated. Obstetric patients with iron deficiency anemia who received intravenous ferric carboxymaltose had a significantly higher level of Hb than those who did not. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Li et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu